Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORZORA olaparib maintenance monotherapy study in platinum-sensitive relapsed BRCA-mutated ovarian cancer
2015-000734-30Phase 4Unknown
- Sponsor
- AstraZeneca
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of olaparib in ovarian cancer, sponsored by AstraZeneca. Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
olaparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2015-000734-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000734-30.